(ORIC) Oric Pharmaceuticals - Ratings and Ratios

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to overcome resistance mechanisms in cancers. The companys pipeline includes several promising candidates targeting specific mutations and pathways critical to cancer progression.

ORIC-114 is a brain-penetrant, orally bioavailable, and irreversible inhibitor targeting EGFR exon 20 and HER2 exon 20 mutations, with high potency against exon 20 insertion mutations. Currently in Phase 1b studies, this candidate addresses a significant unmet need in non-small cell lung cancer (NSCLC) and other EGFR-mutated cancers. ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2), is also in Phase 1b studies for prostate cancer. This compound aims to restore tumor suppressor gene expression in cancers driven by PRC2 dysregulation.

The company is also advancing ORIC-533, an orally bioavailable small molecule inhibitor of CD73, which is being investigated in multiple solid tumors. ORIC-613, another small molecule therapeutic, targets a mechanism of innate resistance in breast cancers. ORIC Pharmaceuticals has established strategic collaborations with major pharmaceutical companies, including Pfizer, Bayer, and Johnson & Johnson, to evaluate its candidates in combination with approved therapies.

Founded in 2014 and headquartered in South San Francisco, California, ORIC Pharmaceuticals is positioned to leverage its expertise in precision oncology to develop targeted therapies for genetically defined cancers. The companys focus on resistance mechanisms and its collaborative approach underscore its commitment to advancing innovative cancer treatments.

3-Month Forecast: Based on and , ORIC Pharmaceuticals stock is expected to face headwinds due to its current price ($7.84) trading below its 20-day, 50-day, and 200-day moving averages ($9.46, $9.22, $9.32, respectively). The average trading volume of 1.7 million shares over 20 days and an ATR of 1.04 suggest moderate volatility. With a negative return on equity (-52.59%) and a price-to-book ratio of 2.24, investor sentiment may remain cautious. The stock is likely to trade in a range between $6.80 and $8.80 over the next three months, with potential selling pressure driven by profitability concerns.